Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18759278 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION | June 2024 | May 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18759260 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION | June 2024 | May 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18674445 | PHARMACEUTICAL FORMULATION | May 2024 | September 2024 | Allow | 4 | 1 | 0 | No | No |
| 18651026 | STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE | April 2024 | August 2024 | Allow | 3 | 1 | 0 | No | No |
| 18651036 | STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18608182 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18604319 | Trans-Epithelial Membrane Drug Delivery System | March 2024 | December 2024 | Allow | 9 | 1 | 0 | No | No |
| 18435221 | RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS | February 2024 | May 2025 | Allow | 15 | 1 | 0 | No | No |
| 18392891 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | December 2023 | June 2025 | Allow | 18 | 0 | 0 | No | No |
| 18520172 | STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE | November 2023 | February 2024 | Allow | 3 | 1 | 0 | No | No |
| 18386863 | STABLE PARENTERAL FORMULATIONS OF DULOXETINE | November 2023 | May 2025 | Allow | 18 | 3 | 0 | No | No |
| 18491243 | RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS | October 2023 | November 2024 | Allow | 13 | 1 | 0 | No | No |
| 18476003 | Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration | September 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18371087 | COMPOSITIONS AND METHODS FOR TREATING DIABETIC FOOT AND OTHER INJURIES AND SORES | September 2023 | May 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18465226 | ANTIBIOTIC COMBINATION THERAPIES | September 2023 | April 2025 | Allow | 19 | 2 | 0 | No | No |
| 18281229 | POLYMERIZABLE 4,4'-SPIROBI[CHROMANE]-2,2'-DIONES AND CURABLE COMPOSITIONS INCLUDING THE SAME | September 2023 | February 2024 | Allow | 5 | 0 | 0 | No | No |
| 18241432 | Cosmetic Material Composition | September 2023 | April 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18450873 | Coupling Agent Produced From Naturally Fermented And Sustainable Additives | August 2023 | December 2024 | Allow | 16 | 1 | 0 | No | No |
| 18447391 | YEAST-BASED MASKS FOR IMPROVED SKIN, HAIR AND SCALP HEALTH | August 2023 | October 2024 | Allow | 14 | 1 | 0 | No | No |
| 18332677 | STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE | June 2023 | September 2023 | Allow | 3 | 1 | 0 | No | No |
| 18201275 | POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | May 2023 | August 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18318117 | DRY MIXTURE AND PERSONAL CARE COMPOSITION AS WELL AS METHODS FOR THEIR PRODUCTION | May 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18313545 | METHOD FOR MODULATING METABOLISM | May 2023 | March 2025 | Allow | 22 | 2 | 0 | No | No |
| 18142699 | CONJUNCTIVAL COVER AND METHODS THEREFOR | May 2023 | May 2024 | Allow | 12 | 1 | 0 | No | No |
| 18307435 | BROMOCRIPTINE FORMULATIONS | April 2023 | August 2024 | Allow | 16 | 2 | 0 | No | No |
| 18299658 | Oral Medicine Delivery Capsule | April 2023 | March 2025 | Allow | 23 | 3 | 0 | Yes | No |
| 18296476 | Pristine and Ultra-reduced Graphene Oxide as a Carrier for Enzymes and Catalysts | April 2023 | March 2024 | Allow | 11 | 2 | 0 | No | No |
| 18130490 | DISSOLVABLE MICRONEEDLES FOR SKIN TREATMENT | April 2023 | July 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18129969 | PHARMACEUTICAL FORMULATION | April 2023 | November 2023 | Abandon | 7 | 1 | 0 | No | No |
| 18247612 | LIPID NANOPARTICLE | March 2023 | June 2025 | Allow | 27 | 0 | 0 | No | No |
| 18124796 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | March 2023 | November 2023 | Allow | 8 | 1 | 0 | No | No |
| 18121795 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | March 2023 | May 2024 | Allow | 14 | 1 | 0 | No | No |
| 18182675 | ORALLY ADMINISTERED COMBINATIONS OF BETA LACTAM ANTIBIOTICS AND AVIBACTAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | March 2023 | April 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18119251 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION | March 2023 | November 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 18172843 | Multi-Targeted Multi-Valent Ligand Drug Particles for the Treatment and Prevention of Diseases and Conditions | February 2023 | April 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18170704 | Remote Loading of Sparingly Water-Soluble Drugs Into Lipid Vesicles | February 2023 | April 2024 | Allow | 13 | 1 | 0 | No | No |
| 18160036 | METHODS OF TREATING TRIPLE-NEGATIVE BREAST CANCER USING COMPOSITIONS OF ANTIBODIES AND CARRIER PROTEINS | January 2023 | August 2023 | Allow | 7 | 1 | 0 | No | No |
| 18085810 | PHARMACEUTICAL FORMULATION | December 2022 | May 2024 | Abandon | 17 | 3 | 1 | No | No |
| 18067605 | STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE | December 2022 | March 2023 | Allow | 3 | 1 | 0 | No | No |
| 18067397 | STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE | December 2022 | March 2023 | Allow | 3 | 1 | 0 | No | No |
| 18067287 | STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE | December 2022 | March 2023 | Allow | 3 | 1 | 0 | No | No |
| 18055595 | Formulations, Methods, and Systems for Treating Genitourinary Conditions | November 2022 | August 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 18047915 | IPA-3-LOADED LIPOSOMES AND METHODS OF USE THEREOF | October 2022 | January 2024 | Allow | 14 | 1 | 0 | No | No |
| 17959768 | DENTAL COMPOSITION COMPRISING A PARTICULATE CARRIER SUPPORTING A COINITIATOR | October 2022 | December 2023 | Allow | 14 | 2 | 0 | No | No |
| 17936184 | Compounds and Compositions for Ossification and Methods Related Thereto | September 2022 | August 2023 | Allow | 10 | 1 | 0 | No | No |
| 17950979 | STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE | September 2022 | January 2023 | Allow | 4 | 1 | 0 | No | No |
| 17950964 | STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE | September 2022 | January 2023 | Allow | 4 | 1 | 0 | No | No |
| 17901688 | METHOD OF TREATMENT OF TOPICAL DERMATOLOGIC ACNE USING A CREAM COMPOSITION AND METHOD OF MANUFACTURE | September 2022 | March 2024 | Allow | 19 | 3 | 0 | Yes | No |
| 17822872 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | August 2022 | September 2023 | Allow | 13 | 1 | 0 | No | No |
| 17887261 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTICS AGENTS | August 2022 | November 2023 | Abandon | 15 | 0 | 1 | No | No |
| 17884727 | Transdermal Drug Delivery System | August 2022 | August 2023 | Allow | 13 | 1 | 0 | No | No |
| 17816427 | IONIZABLE LIPID COMPOUNDS, LIPID NANOPARTICLES COMPRISING SAME AND THERAPEUTIC USES THEREOF | August 2022 | September 2023 | Allow | 13 | 1 | 0 | No | No |
| 17875724 | POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | July 2022 | May 2023 | Allow | 10 | 1 | 0 | No | No |
| 17813875 | METHOD FOR MODULATING METABOLISM | July 2022 | February 2023 | Allow | 7 | 1 | 1 | Yes | No |
| 17812893 | BIODEGRADABLE ALPHA-2 AGONIST POLYMERIC IMPLANTS AND THERAPEUTIC USES THEREOF | July 2022 | January 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17857302 | HIGH-EFFICIENCY ENCAPSULATION OF HYDROPHILIC COMPOUNDS IN UNILAMELLAR LIPOSOMES | July 2022 | May 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17833326 | RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS | June 2022 | July 2023 | Allow | 13 | 1 | 0 | No | No |
| 17826817 | RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS | May 2022 | September 2023 | Allow | 16 | 3 | 0 | No | No |
| 17737712 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | May 2022 | April 2024 | Allow | 23 | 2 | 0 | No | No |
| 17721595 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS | April 2022 | May 2025 | Allow | 37 | 6 | 1 | Yes | Yes |
| 17707230 | TREATMENT METHODS FOR MEDICAL AND DENTAL IMPLANTS, PERIODONTAL DISEASES AND MEDICAL PROCEDURES | March 2022 | August 2022 | Allow | 5 | 1 | 0 | No | No |
| 17703312 | Combination Therapy for Cancer Treatment | March 2022 | July 2023 | Allow | 16 | 1 | 0 | No | No |
| 17699574 | YEAST-BASED MASKS FOR IMPROVED SKIN, HAIR AND SCALP HEALTH | March 2022 | July 2023 | Allow | 16 | 1 | 0 | No | No |
| 17690862 | PROGRAMMABLE POLYMERIC DRUGS | March 2022 | July 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17669840 | Compositions for Treating Joint or Connective Tissue Disease Comprising Dextran or Poloxamer | February 2022 | June 2023 | Allow | 16 | 1 | 0 | No | No |
| 17665938 | HAIR CARE OR HAIR CLEANSING COMPOSITION OR SKIN CARE OR SKIN CLEANSING COMPOSITION | February 2022 | February 2023 | Allow | 13 | 1 | 0 | No | No |
| 17592899 | FULLERENE PHOSPHONATE GALLOYLS AND METHODS | February 2022 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17649826 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | February 2022 | August 2022 | Allow | 6 | 1 | 0 | No | No |
| 17591126 | FULLERENIC ELLAGIC LUTEOLIN AND METHODS | February 2022 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17590421 | Dental Materials Based On Polymerizable Thiourea Derivatives | February 2022 | May 2024 | Allow | 28 | 1 | 0 | No | No |
| 17587639 | SKINCARE SYSTEM | January 2022 | June 2025 | Abandon | 40 | 5 | 0 | No | No |
| 17585431 | Method and Apparatus for Using Iodinated Polymer as an Antimicrobial Agent to Manage the Suppression and Disinfection of Pathogens | January 2022 | September 2022 | Allow | 8 | 1 | 0 | No | No |
| 17581968 | BLEEDING CONTROL DEVICE AND METHOD OF MANUFACTURE AND USE | January 2022 | May 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17574885 | METHODS FOR IMPROVED DELIVERY OF AMINOTHIOLS, DIMERS OF AMINOTHIOLS, AND HETERODIMERS COMPOSED OF AMINOTHIOLS | January 2022 | April 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17575160 | METHODS AND COMPOSITIONS OF PREVENTING AND TREATING DENTAL CARIES | January 2022 | September 2023 | Allow | 20 | 2 | 0 | No | No |
| 17571917 | Protein Beverage Composition | January 2022 | January 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17571158 | Oral Care Compositions | January 2022 | June 2023 | Allow | 18 | 2 | 0 | No | No |
| 17647153 | ESTROGEN RECEPTOR MODULATORS FOR TREATING MUTANTS | January 2022 | June 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17562496 | ANTIBIOTIC COMBINATION THERAPIES | December 2021 | May 2023 | Allow | 17 | 1 | 0 | No | No |
| 17561171 | Coupling Agent Produced From Naturally Fermented And Sustainable Additives | December 2021 | May 2023 | Allow | 17 | 1 | 0 | No | No |
| 17619484 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | December 2021 | June 2024 | Allow | 30 | 2 | 0 | No | No |
| 17539578 | Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration | December 2021 | June 2023 | Allow | 19 | 1 | 0 | No | No |
| 17454626 | METHODS AND COMPOSITIONS FOR INHIBITING FORMATION OF BIOFILMS | November 2021 | December 2023 | Allow | 25 | 1 | 0 | Yes | No |
| 17520098 | DENTAL GLASS IONOMER CEMENT COMPOSITION SUITABLE FOR MECHANICAL MIXING | November 2021 | September 2024 | Allow | 35 | 2 | 0 | No | No |
| 17518759 | CHONDROITIN SULFATE GLYCOSAMINOGLYCAN HYDROGEL MATRICES FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | November 2021 | May 2024 | Allow | 30 | 1 | 0 | No | No |
| 17608793 | FUNGICIDE COMPOSITION FOR CONTROLLING ZYMOSEPTORIA INFECTION IN PLANT | November 2021 | April 2025 | Allow | 42 | 4 | 0 | No | No |
| 17505193 | Oral Care Compositions | October 2021 | July 2023 | Allow | 20 | 2 | 0 | No | No |
| 17504785 | LIPID NANOPARTICLES FOR IN-VIVO DRUG DELIVERY, AND USES THEREOF | October 2021 | May 2022 | Allow | 7 | 1 | 0 | No | No |
| 17501773 | Pain Relief Utilizing Polymer Based Materials Or A Combination Of LED Bulbs And Polymer Based Materials To create A Near Field Accelerator | October 2021 | February 2023 | Allow | 16 | 1 | 0 | No | No |
| 17501230 | METHOD FOR MODULATING METABOLISM | October 2021 | May 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17498741 | Synergistic Mixture for Inducing Hygienic Behavior in Honey Bees, and Related Compositions and Methods | October 2021 | August 2022 | Allow | 10 | 1 | 0 | No | No |
| 17494708 | BIOCOMPATIBLE AND BIODEGRADABLE ANTIVIRAL POLYMERS | October 2021 | May 2024 | Allow | 31 | 1 | 1 | No | No |
| 17598317 | PEST CONTROL KIT AND METHOD | September 2021 | March 2025 | Allow | 42 | 1 | 1 | No | No |
| 17439608 | EFFICIENT SUNSCREEN COMPOSITIONS WITH DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE, BUTYL METHOXYDIBENZOYLMETHANE AND ORGANIC PARTICULATE UV FILTER | September 2021 | May 2024 | Allow | 32 | 2 | 0 | No | No |
| 17439528 | EFFICIENT SUNSCREEN COMPOSITIONS WITH DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE AND BUTYL METHOXYDIBENZOYLMETHANE | September 2021 | May 2025 | Allow | 44 | 1 | 0 | No | No |
| 17458149 | PROGRAMMABLE POLYMERIC DRUGS | August 2021 | December 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17409417 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | August 2021 | September 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17376686 | CONJUNCTIVAL COVER AND METHODS THEREFOR | July 2021 | February 2023 | Allow | 19 | 1 | 0 | No | No |
| 17373434 | L-SERINE COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | July 2021 | March 2024 | Allow | 32 | 4 | 2 | No | No |
| 17370519 | Controlled Release Dosage Form | July 2021 | February 2023 | Allow | 19 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PACKARD, BENJAMIN J.
With a 44.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PACKARD, BENJAMIN J works in Art Unit 1612 and has examined 1,347 patent applications in our dataset. With an allowance rate of 65.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner PACKARD, BENJAMIN J's allowance rate of 65.6% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PACKARD, BENJAMIN J receive 1.82 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by PACKARD, BENJAMIN J is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +20.4% benefit to allowance rate for applications examined by PACKARD, BENJAMIN J. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 25.8% of applications are subsequently allowed. This success rate is in the 32% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 41.1% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 68.5% of appeals filed. This is in the 49% percentile among all examiners. Of these withdrawals, 58.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 41.4% are granted (fully or in part). This grant rate is in the 42% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 2.2% of allowed cases (in the 78% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.